Title of cohort


Study of the relations between global food behaviors and/or specific nutritional factors and ageing on a large population of mature adults

Acronym for cohort


SUVIMAX 2

Name of Principal Investigator - Title


Prof

Name of Principal Investigator - First name


Serge

Name of Principal Investigator - Last name


Hercberg

Address of institution -Institution


INSERM

Address of institution - Street address


EREN, SMBH, 74 rue Marcel Cachin

Address of institution - City


Bobigny

Address of institution - Postcode


93017

Country


France

Website


Contact email


[email protected]

Funding source


NR, Inserm, MGEN, Mederic, IPSEN, Pierre Fabre

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?


Already possible

Q2a. In a single sentence what is the stated aim of the cohort?


Study the relations between global eating behaviors and/or some specific nutritional factors an the global quality of ageing among this population

Q2b. What distinguishes this cohort from other population cohorts?


Clinical, biological and neuropsychological data as well as nutritional exposure

Q3a. i) Number of publications that involve use of your cohort to date


220

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)


Emmanuelle Kesse-Guyot, INRA, Healthy aging and Nutrition| Emmanuelle Kesse-Guyot, INRA, Cognitive performances and Nutrition

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


https://www.dropbox.com/s/yjgydbdzy4zng1x/Biblio%20SUVIMAX2.rtf?dl=0

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population


Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


55

Q4a. Study criteria: what is the age range of participants at recruitment? To:


70

Q4b. Study criteria: what are the inclusion criteria?


Voluntary subjects, having participated to the SUI.VI.MAX cohort, and aged between 55 and 70.

Q4c. Study criteria: what are the exclusion criteria?


Q5. What is the size of the cohort (i.e. how many participants have enrolled)?


5,001-10,000 participants

Q6a. Please describe what measures are used to characterise participants


We are working on health during aging overall. Clinical, biological and neuropsychological data have benne collected.

Q6b. Are there additional measures for participants with a clinical disorder?


Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


If yes please specify


Q7. What is the study design (select all that apply)?


Prospective cohort|Longitudinal

Q8. Are your cases matched by


Q9a. Does your study include a specialised subset of control participants?


No

Q9b. If your study includes a specialised subset of control participants please describe


Q10a. i) Please enter the data collection start date


01/01/2007

Q10a. ii) Please enter the data collection end date


01/01/2009

Q10a. iii) Is data collection for this study


Data analysis ongoing| Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Q11. Is data collected


Only through the study

Other please specify here


Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?


Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)


Data summarised in database

% available


Q13a. Please give information on the format and availability of data stored in a database (2)


No

% available


Q13a. Please give information on the format and availability of data stored in a database (3)


No

% available


Q13a. Please give information on the format and availability of data stored in a database (4)


No

% available


Other (please specify)


% available


Q13b. Please give information on the format and availability of data held as individual records (1)


% available


Q13b. Please give information on the format and availability of data held as individual records (2)


% available


Q13b. Please give information on the format and availability of data held as individual records (3)


% available


Q13b. Please give information on the format and availability of data held as individual records (4)


% available


Please specify language used


Q14a. Is data available to other groups?


Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Apply to PI or co-ordinator at resource| Access to industry

Q15. What data sharing policy is specified as a condition of use?


No policy exists

Q16a. Are tissues/samples/DNA available to other groups?


Yes

Q16b i) If yes, please describe below:


Living donors blood| Living donors: blood derivatives| Living donors: DNA

Q16b. ii) In what form are tissues/samples/DNA supplied?


Secondary samples: plasma| Secondary samples: DNA| Secondary samples: other (Serum)

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


Yes

Q17. Is information on biological characteristics available to other groups?


If available for a subset please specify number of patients and % of total cohort

Number of Patients


3500

% of total cohort


50

Export as PDF